| Impact of hospitalisation on health-related quality of life in patients with chronic heart failure F Albuquerque de Almeida, MJ Al, R Koymans, J Riistama, S Pauws, ... Health and Quality of Life Outcomes 18, 1-10, 2020 | 23 | 2020 |
| Pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib: an evidence review group perspective … NC Büyükkaramikli, S de Groot, D Fayter, R Wolff, N Armstrong, L Stirk, ... PharmacoEconomics 36 (2), 145-159, 2018 | 14 | 2018 |
| Biologicals and biosimilars: safety issues in Europe MCC Portela, C Sinogas, F Albuquerque de Almeida, R Baptista-Leite, ... Expert opinion on biological therapy 17 (7), 871-877, 2017 | 10 | 2017 |
| Early warning systems for the management of chronic heart failure: a systematic literature review of cost-effectiveness models F Albuquerque De Almeida, M Al, R Koymans, K Caliskan, A Kerstens, ... Expert review of pharmacoeconomics & outcomes research 18 (2), 161-175, 2018 | 7 | 2018 |
| Modeling early warning systems: construction and validation of a discrete event simulation model for heart failure FA de Almeida, IC Ramos, M Rutten-van Mölken, M Al Value in Health 24 (10), 1435-1445, 2021 | 6 | 2021 |
| Biologicals and biosimilars: gaps in the pharmacovigilance system in Portugal EMCC Portela, C Sinogas, FA Almeida, R Baptista-Leite, A Castro-Caldas Acta medica portuguesa 30 (3), 205-212, 2017 | 4 | 2017 |
| Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer S Smith, FA de Almeida, M Inês, L Iadeluca, M Cooper Value in Health 26 (1), 64-70, 2023 | 3 | 2023 |
| Home Telemonitoring and a Diagnostic Algorithm in the Management of Heart Failure in the Netherlands: Cost-effectiveness Analysis F Albuquerque de Almeida, I Corro Ramos, M Al, M Rutten-van Mölken JMIR cardio 6 (2), e31302, 2022 | 3 | 2022 |
| Different regulatory framework for medical devices and drugs in the European Union: Impact on clinical research and health technology assessments F Albuquerque de Almeida, M Ricardo The International Journal of Health Planning and Management, 2023 | 2 | 2023 |
| Medicamentos Biológicos e Biossimilares: Descontinuidades no Sistema de Farmacovigilância em Portugal MCC Portela, C Sinogas, FA de ALMEIDA, R Baptista-Leite, ... Acta Médica Portuguesa 30 (3), 205-212, 2017 | 1 | 2017 |
| Impact on Quality of Life by Clostridioides difficile Infections among Hospitalized Patients in Japan A IGARASHI, FA de ALMEIDA, FJ ANGULO, S ITO, MC MACULAITIS, ... Kansenshogaku Zasshi 98 (1), 8-19, 2024 | | 2024 |
| EE245 Impact of Modelling the Inclusion of Productivity Losses in Economic Analyses of Vaccines for Clostridioides Difficile Infections and Respiratory Syncytial Virus JC Mewes, M Neri, FA de Almeida, S Stoychev, N Minarovic, A Charos, ... Value in Health 25 (12), S101, 2022 | | 2022 |
| EE52 Defining and Measuring Health System Pressure: A Conceptual Framework and Application to RSV and C. Difficile Infections M Neri, S Brassel, H Schirrmacher, L Steuten, KM Shea, S Stoychev, ... Value in Health 25 (7), S345, 2022 | | 2022 |
| Economic Evaluation of Early Warning Systems for Chronic Disease Management: The Case of Heart Failure F Albuquerque de Almeida | | 2021 |
| PCN68 An Incremental Effectiveness Analysis of Lorlatinib for the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer that has Progressed after Another ALK Tyrosine … R Guerreiro, AT Paquete, L Iadeluca, C Almond, FA de Almeida, M Inês, ... Value in Health 23, S433, 2020 | | 2020 |
| PCN6 Matching-Adjusted Indirect Treatment Comparisons (MAIC) of the Effect of Lorlatinib Versus Chemotherapy on Overall Survival (OS) and Progression-Free Survival (PFS) for … S Smith, FA de Almeida, M Inês, L Iadeluca, M Cooper Value in Health 23, S421-S422, 2020 | | 2020 |
| PDG24 The Cost-Effectiveness of Isavuconazole in the Treatment of Invasive Fungal Infections in Portugal M Inês, C Palos, FA de Almeida, LS Miguel, F Lourenço, M Borges Value in Health 23, S524, 2020 | | 2020 |
| Biologicals and Biosimilars: Gaps in the Pharmacovigilance System in Portugal Medicamentos Biológicos e Biossimilares: Descontinuidades no Sistema de Farmacovigilância em Portugal MCC PORTELA, C SINOGAS, FA de ALMEIDA, R BAPTISTA-LEITE, ... | | |
